Brookdale Senior Living (BKD) Appoints Joshua Hausman to its Board

Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale" or the "Company") today announced that its Board of Directors (the "Board") has appointed Joshua Hausman, Managing Partner at MHJ Capital Partners and former Managing Director at Onex Partners, as an independent director, effective April 24, 2025.

Denise W. Warren, Interim Chief Executive Officer and Chairman of the Board, said, "Josh has over 20 years of private market investment experience focused on the healthcare industry, including in facilities-based skilled nursing and behavioral health. He brings an owner mindset, having collaborated with management teams in devising and executing growth and operating strategies. We are confident we will benefit from his deep expertise and insights as we focus on accelerating profitable occupancy and RevPAR growth, delivering meaningful Adjusted EBITDA growth, materially enhancing Adjusted Free Cash Flow generation, and creating shareholder value."

Mr. Hausman joins the Brookdale Board following the recent appointment of Mark Fioravanti as an independent director. With these two appointments and Frank M. Bumstead's decision not to stand for re-election at the 2025 Annual Meeting of Stockholders (the "Annual Meeting"), Brookdale's Board will have an average tenure of less than four years after the Company's 2025 Annual Meeting and comprise eight directors, seven of whom will be independent, including two appointed last year and two this year.

Ms. Warren added, "The continuing refreshment of our Board with highly qualified directors reflects our commitment to bringing in new expertise and perspectives and follows engagement with our shareholders."

As previously announced, the Board is also reviewing potential governance enhancements related to director tenure and evaluating revisions to the Company's performance-based long-term incentive awards program for executives.

You May Also Be Interested In

• Holcim to acquire Fermacell from James Hardie for EUR 840M
• Largo restructures $82.2M in debt, extending maturity to 2030
• Pyxis Oncology (PYXS) files for 39.2M share offering by selling stockholders